

May 27, 2025

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

Sub: Intimation of Outcome of Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we wish to inform you that the Board of Directors of Indegene Ltd., at its meeting held today, i.e., May 27, 2025, has, inter alia, approved that the 27th Annual General Meeting (AGM) of the Company will be held on Thursday, June 26, 2025, at 04:30 p.m. (IST) through Video Conferencing (VC) / Other Audio-Visual Means (OAVM), in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (SEBI).

As informed earlier, the Board of Directors of the Company, at its meeting held on April 28, 2025, had recommended a final dividend of ₹2/- per equity share of face value ₹2/- each for the financial year ended March 31, 2025, subject to approval of the shareholders at the ensuing AGM.

Pursuant to Regulation 42 of the SEBI LODR Regulations, the Company has fixed Friday, June 13, 2025, as the 'Record Date' for determining the eligibility of Members for receiving the aforesaid final dividend, for the financial year ended March 31, 2025.

We further inform that, the Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, approved the continuation of directorship of Dr. Georgia Nikolakopoulou Papathomas (DIN: 09734940) ("Dr. Papathomas"), Independent Director, in terms of regulation 17(1A) of the SEBI LODR Regulations.

The Board has further approved re-appointment of Dr. Georgia Nikolakopoulou Papathomas (DIN: 09734940) as an Independent Woman Director of the Company for a second term of five (5) consecutive years, with effect from October 1, 2025, subject to approval of the shareholders at the ensuing AGM.




Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara,
Bengaluru- 560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: L73100KA1998PLC102040



In terms of NSE circular NSE/CML/2018/24 dated June 20, 2018 and BSE circular LIST/COMP/14/2018-19 dated June 20, 2018, we hereby affirm that Dr. Georgia Nikolakopoulou Papatomas is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The Board also approved allotment under ESOP Scheme 2020.

The disclosure as required under Regulation 30 of SEBI LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is mentioned in "Annexure-I".

The meeting of the Board of Directors commenced at 19:30 hours and concluded at 19:38 hours.

The above information is being made available on the website of the Company at <https://www.indegene.com/>.

This is for your information and records.

Yours Sincerely,

For Indegene Limited

Srishti Ramesh Kaushik
Company Secretary and Compliance Officer


Annexure- I

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated June 13, 2023.

S. No.	Particulars	Details
1.	Name of Director	Dr. Georgia Nikolakopoulou Papatomas (DIN: 09734940)
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment of Dr. Georgia Nikolakopoulou Papatomas as an Independent Woman Director for a second term of 5 years, subject to approval of the shareholders.
3.	Date of appointment, re- appointment, cessation and terms of appointment	October 01, 2025 Term: For a second term of 5 years with effect from 01 October 2025 to 30 September 2030.
4.	Brief Profile (In case of appointment)	<p>Dr. Papatomas is the former Vice President and Chief Information Officer, J&J Pharmaceuticals.</p> <p>She is a former member of the J&J Pharmaceuticals Group Operating Committee (GOC) and Chief Information Officer for the Group of J&J Pharmaceutical Companies.</p> <p>Prior to joining J&J, Dr. Papatomas held the position of Senior Vice President-Chief Information Officer at Boehringer Ingelheim Pharmaceutical in Ridgefield, Connecticut. She was a member of the BI-Pharmaceuticals Executive Leadership Team.</p> <p>Dr. Papatomas has worked with Pfizer as the Chief Technology Officer (CTO) for EMEA and as Vice President-Global Customer Service Management; Lucent Technologies as Vice President-Global Professional Services/Network Solutions; and started her career in research at AT&T Bell Labs.</p> <p>She received her Ph.D. engineering science; her MS engineering mechanics, Sloan Fellowship; and BS civil engineering all from Columbia University.</p> <p>Among her many affiliations, she is on the Board of the National Center for Women in Information Technology, on the Board of Homeless Solutions and</p>



		<p>on the Board of Visitors of the Columbia University School of Engineering and Applied Sciences.</p> <p>Dr. Papathomas is also a member of the New York Academy of Sciences, the Sigma Xi Research honor society, the Gartner Research Board and the American Association for the Advancement of Science.</p>
5.	Disclosure of relationship between directors (In case of appointment)	Not related to any Director of the Company.